Pharmacokinetic and pharmacodynamic interactions between antiepileptics and antidepressants

Bibliography

• Johannessen Landmark C. Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. CNS Drugs 2008;22:27-47
   PubMed Web of Science ®Google Scholar
• Bialer M. Why are antiepileptic drugs used for nonepileptic conditions? Epilepsia 2012;53(Suppl 7):26-33
   PubMedGoogle Scholar
• Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 2007;369:1016-26
   PubMed Web of Science ®Google Scholar
• Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblended randomised controlled trial. Lancet 2007;369:1000-15
   PubMed Web of Science ®Google Scholar
• Stahl SM. Antidepressants. In: Stahl SM, editor. Stahl’s Essential Psychopharmacology. 4th edition. Cambridge University Press, New York; 2013. p. 284-369
   Google Scholar
• Hermann B, Seidenberg M, Bell B. Psychiatric comorbidity in chronic epilepsy: identification, consequences, and treatment of major depression. Epilepsia 2000;41:S31-41
   PubMed Web of Science ®Google Scholar
• Prueter C, Norra C. Mood disorders and their treatment in patients with epilepsy. J Neuropsychiatry Clin Neurosci 2005;17:20-8
   PubMed Web of Science ®Google Scholar
• Mula M, Schmitz B, Sander WJ. The pharmacological treatment of depression in adults with epilepsy. Expert Opin Pharmacother 2008;9:3159-68
   PubMed Web of Science ®Google Scholar
• Mula M, Schmitz B. Depression in epilepsy: mechanisms and therapeutic approach. Ther Adv Neurol Disord 2009;2:337-44
   PubMedGoogle Scholar
• Kanner AM. The treatment of depressive disorders in epilepsy: what all neurologists should know. Epilepsia 2013;54:3-12
   PubMed Web of Science ®Google Scholar
• Mehndiratta P, Sajatovic M. Treatments for patients with comorbid epilepsy and depression: a systematic literature review. Epilepsy Behav 2013;28:36-40
   PubMed Web of Science ®Google Scholar
• Harden CL, Goldstein MA. Mood disorders in patients with epilepsy: epidemiology and management. CNS Drugs 2002;16:291-302
   PubMed Web of Science ®Google Scholar
• Geddes JR, Miklowitz DJ. Treatment of bipolar disorder. Lancet 2013;381:1672-82
   PubMed Web of Science ®Google Scholar
• Grunze HC. Anticonvulsants in bipolar disorder. J Ment Health 2010;19:127-41
   PubMed Web of Science ®Google Scholar
• Vieta E, Valentí M. Pharmacological management of bipolar depression: acute treatment, maintenance, and prophylaxis. CNS Drugs 2013;27:515-29
   PubMed Web of Science ®Google Scholar
• Mula M. Investigating psychotropic properties of antiepileptic drugs. Expert Rev Neurother 2013;13:639-46
   PubMed Web of Science ®Google Scholar
• Tan T, Barry P, Reken S, Baker M; Guideline Development Group. Pharmacological management of neuropathic pain in non-specialist settings: summary of NICE guidance. BMJ 2010;340:c1079
   PubMedGoogle Scholar
• Dworkin RH, O’Connor AB, Audette J. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 2010;85:S3-14
   PubMed Web of Science ®Google Scholar
• Chaparro LE, Wiffen PJ, Moore RA, Gilron I. Combination pharmacotherapy for the treatment of neuropathic pain in adults. Cochrane Database Syst Rev 2012;7:CD008943
   PubMed Web of Science ®Google Scholar
• Rickels K, Shiovitz TM, Ramey TS, et al. Adjunctive therapy with pregabalin in generalized anxiety disorder patients with partial response to SSRI or SNRI treatment. Int Clin Psychopharmacol 2012;27:142-50
   PubMed Web of Science ®Google Scholar
• Vitali M, Tedeschini E, Mistretta M, et al. Adjunctive pregabalin in partial responders with major depressive disorder and residual anxiety. J Clin Psychopharmacol 2013;33:95-8
   PubMed Web of Science ®Google Scholar
• Casucci G, Villani V, Cologno D, D’Onofrio F. Polytherapy for migraine prophylaxis. Neurol Sci 2012;33:S147-50
   PubMedGoogle Scholar
• Silberstein SD, Holland S, Freitag F, et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012;78:1337-45
   PubMed Web of Science ®Google Scholar
• Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol 2003;2:347-56
   PubMed Web of Science ®Google Scholar
• Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol 2003;2:473-81
   PubMed Web of Science ®Google Scholar
• Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 2006;61:246-55
   PubMed Web of Science ®Google Scholar
• Johannesen Landmark C, Patsalos P. Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert Rev Neurother 2010;10:119-40
   PubMed Web of Science ®Google Scholar
• de Leon J, Santoro V, D’Arrigo C, Spina E. Interactions between antiepileptics and second-generation antipsychotics. Exp Opin Drug Metab Toxicol 2012;8:311-34
   PubMed Web of Science ®Google Scholar
• Nemeroff CB, Preskorn S, Devane CL. Antidepressant drug-drug interactions: clinical relevance and risk management. CNS Spectr 2007;12:1-13
   Google Scholar
• Schellander R, Donnerer J. Antidepressants: clinically relevant drug interactions to be considered. Pharmacology 2010;86:203-15
   PubMed Web of Science ®Google Scholar
• Spina E, Santoro V, D’Arrigo C. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther 2008;30:1206-27
   PubMed Web of Science ®Google Scholar
• Spina E, Trifirò G, Caraci F. Clinically significant drug interactions with newer antidepressants. CNS Drugs 2012;26:39-67
   PubMed Web of Science ®Google Scholar
• Spina E, de Leon J. Clinically relevant interactions between newer antidepressants and second-generation antipsychotics. Exp Opin Drug Metab Toxicol 2014;10:712-46
   Google Scholar
• Spina E, Perucca E. Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs. Epilepsia 2002;43(Suppl 2):37-44
   PubMed Web of Science ®Google Scholar
• Mula M. Anticonvulsants-antidepressants pharmacokinetic drug interactions: the role of the CYP450 system in psychopharmacology. Curr Drug Metab 2008;8:730-7
   Google Scholar
• DeVane CL. Clinical significance of drug binding, protein binding, and binding displacement drug interactions. Psychopharmacol Bull 2002;36:5-21
   PubMedGoogle Scholar
• Spina E. Drug interactions. In: Shorvon S, Perucca E, Engel J, editors. Treatment of Epilepsy. 3rd edition. Wiley-Blackwell Publishing Ltd, Oxford; 2009. p. 361-77
   Google Scholar
• Cozza KL, Armstrong SC, Oesterheld JR. Concise guide to drug interaction principles for medical practice: cytochrome P450s, UGTs, P-Glycoproteins. 2nd edition. American Psychiatric Association, Washington, DC; 2003
   Google Scholar
• Shin JG, Park JY, Kim MJ, et al. Inhibitory effects of tricyclic antidepressants (TCAs) on human cytochrome P450 enzymes in vitro: mechanism of drug interaction between TCAs and phenytoin. Drug Metab Dispos 2002;30:1102-7
   PubMed Web of Science ®Google Scholar
• Lin JH. Transporter-mediated drug interactions. Clinical implications and in vitro assessment. Exp Opin Drug Metab Toxicol 2007;3:81-92
   PubMed Web of Science ®Google Scholar
• Zhang C, Kwan P, Zuo Z, Baum L. The transport of antiepileptic drugs by P-glycoprotein. Adv Drug Deliv Rev 2012;64:930-42
   PubMed Web of Science ®Google Scholar
• O’Brien FE, Dinan TG, Griffin BT, Cryan JF. Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: clinical significance of in vitro and in vivo findings. Br J Pharmacol 2012;165:289-312
   PubMed Web of Science ®Google Scholar
• Akamine Y, Yasui-Furukori N, Ieiri I, Uno T. Psychotropic drug-drug interactions involving P-glycoprotein. CNS Drugs 2012;26:959-73
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Mintzer S, Pack AM, et al. Enzyme induction with antiepileptic drugs: cause for concern? Epilepsia 2013;54:11-27
   PubMed Web of Science ®Google Scholar
• Vrzal R, Doricakova A, Novotna A, et al. Valproic acid augments vitamin D receptor-mediated induction of CYP24 by vitamin D3: a possible cause of valproic acid-induced osteomalacia? Toxicol Lett 2011;200:146-53
   PubMed Web of Science ®Google Scholar
• Miziak B, Błaszczyk B, Chrościńska-Krawczyk M, et al. The problem of osteoporosis in epileptic patients taking antiepileptic drugs. Expert Opin Drug Saf 2014;13:935-46
   PubMed Web of Science ®Google Scholar
• de Leon J. Glucuronidation enzymes, genes and psychiatry. Int J Neuropsychopharmacol 2003;6:57-72
   PubMed Web of Science ®Google Scholar
• Benedetti MS, Whomsley R, Baltes E, Tonner F. Alteration of thyroid hormone homeostasis by antiepileptic drugs in humans: involvement of glucuronosyltransferase induction. Eur J Clin Pharmacol 2005;61:863-72
   PubMed Web of Science ®Google Scholar
• Sheth RD, Montouris G. Metabolic effects of AEDs: impact on body weight, lipids and glucose metabolism. Int Rev Neurobiol 2008;83:329-46
   PubMed Web of Science ®Google Scholar
• Isojärvi JI, Taubøll E, Herzog AG. Effect of antiepileptic drugs on reproductive endocrine function in individuals with epilepsy. CNS Drugs 2005;19:207-23
   PubMed Web of Science ®Google Scholar
• Jakubus T, Michalska-Jakubus M, Lukawski K, et al. Atherosclerotic risk among children taking antiepileptic drugs. Pharmacol Rep 2009;61:411-23
   PubMed Web of Science ®Google Scholar
• Belcastro V, Striano P. Antiepileptic drugs, hyperhomocysteinemia and B-vitamins supplementation in patients with epilepsy. Epilepsy Res 2012;102:1-7
   PubMed Web of Science ®Google Scholar
• Hill DS, Wlodarczyk BJ, Palacios AM, Finnell RH. Teratogenic effects of antiepileptic drugs. Expert Rev Neurother 2010;10:943-59
   PubMed Web of Science ®Google Scholar
• Labbate LA, Fava M, Rosenbaum JF, et al. Handbook of psychiatric drug therapy. Lippincott Williams & Wilkins, Philadelphia; 2010
   Google Scholar
• Venkatakrishnan K, Greenblatt DJ, von Moltke LL, et al. Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: dominance of CYP 2C19 and 3A4. J Clin Pharmacol 1998;38:112-21
   PubMed Web of Science ®Google Scholar
• Breyer-Pfaff U. The metabolic fate of amitriptyline, nortriptyline and amitriptylinoxide in man. Drug Metab Rev 2004;36:723-46
   PubMed Web of Science ®Google Scholar
• Spina E, Avenoso A, Campo GM, et al. Phenobarbital induces the 2-hydroxylation of desipramine. Ther Drug Monit 1996;18:60-4
   PubMed Web of Science ®Google Scholar
• Spina E, Avenoso A, Campo GM, et al. The effect of carbamazepine on the 2-hydroxylation of desipramine. Psychopharmacology (Berl) 1995;117:413-16
   PubMed Web of Science ®Google Scholar
• Szymura-Oleksiak J, Wyska E, Wasieczko A. Pharmacokinetic interaction between imipramine and carbamazepine in patients with major depression. Psychopharmacology (Berl) 2001;154:38-42
   PubMed Web of Science ®Google Scholar
• Greb WH, Buscher G, Dierdorf HD, et al. The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine. Acta Psychiatry Scand Suppl 1989;350:95-8
   PubMedGoogle Scholar
• Andersen BB, Mikkelsen M, Vesterager A, et al. No influence of the antidepressant paroxetine on carbamazepine, valproate and phenytoin. Epilepsy Res 1991;10:201-4
   PubMed Web of Science ®Google Scholar
• Kahn A, Shad MU, Preskhorn SH. Lack of sertraline efficacy probably due to an interaction with carbamazepine. J Clin Psychiatry 2000;61:526-7
   PubMed Web of Science ®Google Scholar
• Steinacher L, Vandel P, Zullino DF, et al. Carbamazepine augmentation in depressive patients non-responding to citalopram: a pharmacokinetic and clinical pilot study. Eur Neuropsychopharmacol 2002;12:255-60
   PubMed Web of Science ®Google Scholar
• Puozzo C, Leonard BE. Pharmacokinetics of milnacipran in comparison with other antidepressants. Int Clin Psychopharmacol 1996;11(Suppl 4):15-27
   PubMed Web of Science ®Google Scholar
• Sitsen J, Maris F, Timmer C. Drug-drug interaction studies with mirtazapine and carbamazepine in healthy male subjects. Eur J Drug Metab Pharmacokinet 2001;26:109-21
   PubMed Web of Science ®Google Scholar
• Spaans E, van den Heuvel MW, Schnabel PG, et al. Concomitant use of mirtazapine and phenytoin: a drug-drug interactions study in healthy male subjects. Eur J Clin Pharmacol 2002;58:423-9
   PubMed Web of Science ®Google Scholar
• Ketter TA, Jenkins JB, Schroeder DH, et al. Carbamazepine but not valproate induces bupropion metabolism. J Clin Psychopharmacol 1995;15:327-33
   PubMed Web of Science ®Google Scholar
• Helland A, Spigset O. Low serum concentrations of reboxetine in 2 patients treated with CYP3A4 inducers. J Clin Psychopharmacol 2007;27:308-10
   PubMed Web of Science ®Google Scholar
• Cerveny L, Svecova L, Anzenbacherova E, et al. Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways. Drug Metab Dispos 2007;35:1032-41
   PubMed Web of Science ®Google Scholar
• de Leon J. False-negative studies may systematically contaminate the literature on the effects of inducers in neuropsychopharmacology. Part II: focus on bipolar disorder. J Clin Psychopharmacol 2014;34:291-6
   PubMed Web of Science ®Google Scholar
• Vandel S, Bertschy G, Jounet JM, et al. Valpromide increases the plasma concentrations of amitriptyline and its metabolite nortriptyline in depressive patients. Ther Drug Monit 1988;10:386-9
   PubMed Web of Science ®Google Scholar
• Bertschy G, Vandel S, Jounet JM, Allers G. Valpromide-amitriptyline interaction: increase in the bioavailability of amitriptyline and nortriptyline caused by valpromide. Encephale 1990;16:43-5
   PubMedGoogle Scholar
• Wong SL, Cavanaugh J, Shi H, et al. Effects of divalproex sodium on amitriptyline and nortriptyline pharmacokinetics. Clin Pharmacol Ther 1996;60:48-53
   PubMed Web of Science ®Google Scholar
• Fu C, Katzman M, Goldbloom DS. Valproate/nortriptyline interaction. J Clin Psychopharmacol 1994;14:205-6
   PubMed Web of Science ®Google Scholar
• Fehr C, Grunder G, Hiemke C, Dahmen N. Increase of serum clomipramine concentrations caused by valproate. J Clin Psychopharmacol 2000;20:493-4
   PubMed Web of Science ®Google Scholar
• Avoni P, Riva R, Albani F. Recurrence of absence seizures induced by a low dose of amitriptyline. Eur J Neurol 1996;3:272-4
   PubMed Web of Science ®Google Scholar
• DeToledo JC, Haddad H, Ramsay RE. Status epilepticus associated with the combination of valproic acid and clomipramine. Ther Drug Monit 1997;19:71-3
   PubMed Web of Science ®Google Scholar
• Roberts-Thomson KC, Teo KS, Young GD. Drug-induced Brugada syndrome with ST-T wave alternans and long QT. Intern Med J 2007;37:199-200
   PubMed Web of Science ®Google Scholar
• Unterecker S, Burger R, Hohage A, et al. Interaction of valproic acid and amitriptyline: analysis of therapeutic drug monitoring data under naturalistic conditions. J Clin Psychopharmacol 2013;33:561-4
   PubMed Web of Science ®Google Scholar
• Unterecker S, Reif A, Hempel S, et al. Interaction of valproic acid and the antidepressants doxepin and venlafaxine: analysis of therapeutic drug monitoring data under naturalistic conditions. Int Clin Psychopharmacol 2014;29:206-11
   PubMed Web of Science ®Google Scholar
• Kirchheiner J, Meineke I, Muller G, et al. Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- ad Z-doxepin in healthy volunteers. Pharmacogenetics 2002;12:571-80
   PubMedGoogle Scholar
• Fogelman SM, Schmider J, Venkatakrishnan K, et al. O- and N-demethylation of venlafaxine in vitro by human liver microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants. Neuropsychopharmacology 1999;20:480-90
   PubMed Web of Science ®Google Scholar
• Baird P. The interactive metabolism effect of oxcarbazepine coadministered with tricyclic antidepressant therapy for OCD symptoms. J Clin Psychopharmacol 2003;23:419-20
   PubMed Web of Science ®Google Scholar
• Hemeryck A, Belpaire FM. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. Curr Drug Metab 2002;3:13-37
   PubMed Web of Science ®Google Scholar
• Jalil P. Toxic reaction following the combined administration of fluoxetine and phenytoin: two case reports. J Neurol Neurosurg Psychiatry 1992;55:412-13
   PubMed Web of Science ®Google Scholar
• Darley J. Interaction between phenytoin and fluoxetine. Seizure 1994;3:151-2
   PubMedGoogle Scholar
• Woods DJ, Coulter DM, Pillans P. Interaction of phenytoin and fluoxetine. N Z Med J 1994;107:19
   PubMedGoogle Scholar
• Shader RI, Greenblatt DJ, Von Moltke LL. Fluoxetine inhibition of phenytoin metabolism. J Clin Psychopharmacol 1994;14:375-6
   PubMed Web of Science ®Google Scholar
• Pearson HJ. Interaction of fluoxetine with carbamazepine. J Clin Psychiatry 1990;51:126
   PubMed Web of Science ®Google Scholar
• Grimsley SR, Jann MW, Carter JG, et al. Increased carbamazepine plasma concentrations after fluoxetine coadmnistration. Clin Pharmacol Ther 1991;50:10-15
   PubMed Web of Science ®Google Scholar
• Spina E, Avenoso A, Pollicino AM, et al. Carbamazepine coadministration with fluoxetine or fluvoxamine. Ther Drug Monit 1993;15:247-50
   PubMed Web of Science ®Google Scholar
• Sovner R, Davis JM. A potential drug interaction between fluoxetine and valproic acid. J Clin Psychopharmacol 1991;11:389
   PubMed Web of Science ®Google Scholar
• Cruz-Flores S, Hayat GR, Mirza W. Valproic acid toxicity with fluoxetine therapy. Mo Med 1995;92:296-7
   PubMedGoogle Scholar
• Lucena MI, Blanco E, Corrales MA, Berthier ML. Interaction of fluoxetine and valproic acid. Am J Psychiatry 1998;155:575
   PubMed Web of Science ®Google Scholar
• Reimers A, Skogvoll E, Sund JK, Spigset O. Drug interaction between lamotrigine and psychoactive drugs. J Clin Psychopharmacol 2005;25:342-8
   PubMed Web of Science ®Google Scholar
• Fritze J, Unsorg B, Lanczik M. Interaction between carbamazepine and fluvoxamine. Acta Psychiatr Scand 1991;84:583-4
   PubMed Web of Science ®Google Scholar
• Bonnet P, Vandel S, Nezelof S, et al. Carbamazepine, fluvoxamine. Is there a pharmacokinetic interaction? Therapie 1992;47:165
   PubMed Web of Science ®Google Scholar
• Mamiya K, Kojima K, Yukawa E, et al. Phenytoin intoxication induced by fluvoxamine. Ther Drug Monit 2001;23:75-7
   PubMed Web of Science ®Google Scholar
• Rapeport WG, Muirhead DC, Williams SA, et al. Absence of effect of sertraline on the pharmacokinetics and pharmacodynamics of phenytoin. J Clin Psychiatry 1996;57(Suppl 1):24-8
   PubMedGoogle Scholar
• Rapeport WG, Williams SA, Muirhead DC, et al. Absence of sertraline-mediated effect of the pharmacokinetics and pharmacodynamics of carbamazepine. J Clin Psychiatry 1996;57(Suppl 1):20-3
   PubMed Web of Science ®Google Scholar
• Berigan TR, Harazin J. A sertraline/valproic acid drug interaction. Int J Psychiatry Clin Pract 1999;3:287-8
   PubMedGoogle Scholar
• Kaufman KR, Gerner R. Lamotrigine toxicity secondary to sertraline. Seizure 1998;7:163-5
   PubMed Web of Science ®Google Scholar
• Christensen J, Sandgaard AP, Sidenius P, et al. Lack of interaction between sertraline and lamotrigine in psychiatric patients: a retrospective study. Pharmacopsychiatry 2012;45:119-21
   PubMed Web of Science ®Google Scholar
• Von Moltke LL, Greenblatt DJ, Grassi JM, et al. Citalopram and desmethylcitalopram in vitro: human cytochromes mediating transformation, and cytochrome inhibitory effects. Biol Psychiatry 1999;46:839-44
   PubMed Web of Science ®Google Scholar
• Von Moltke LL, Greenblatt DJ, Giancarlo GM, et al. Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug Metab Dispos 2001;29:1102-9
   PubMed Web of Science ®Google Scholar
• Moller SE, Larsen F, Khan AZ, Rolan PE. Lack of effect of citalopram on the steady-state pharmacokinetics of carbamazepine in healthy male subjects. J Clin Psychopharmacol 2001;21:493-9
   PubMed Web of Science ®Google Scholar
• Popli AP, Tanquary J, Lamparella V, Masand PS. Bupropion and anticonvulsant drug interactions. Ann Clin Psychiatry 1995;7:99-101
   PubMedGoogle Scholar
• Odishaw J, Chen C. Effects of steady-state bupropion on the pharmacokinetics of lamotrigine in healthy subjects. Pharmacotherapy 2000;20:1448-53
   PubMed Web of Science ®Google Scholar
• Vigo DV, Baldessarini RJ. Anticonvulsants in the treatment of major depressive disorder: an overview. Harv Rev Psychiatry 2009;17:231-41
   PubMed Web of Science ®Google Scholar
• Malhi GS, Hitching R, Berk M, et al. Pharmacological management of unipolar depression. Acta Psychiatr Scand Suppl 2013;443:6-23
   PubMedGoogle Scholar
• Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol 2014;28:403-39
   PubMed Web of Science ®Google Scholar
• O’Connor AB, Dworkin RH. Treatment of neuropathic pain: an overview of recent guidelines. Am J Med 2009;122:S22-32
   PubMed Web of Science ®Google Scholar
• Gilron I, Bailey JM, Tu D, et al. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial. Lancet 2009;374:1252-61
   PubMed Web of Science ®Google Scholar
• Nishihara M, Arai YC, Yamamoto Y, et al. Combinations of low-dose antidepressants and low-dose pregabalin as useful adjuvants to opioids for intractable, painful bone metastases. Pain Physician 2013;16:E547-52
   PubMed Web of Science ®Google Scholar
• Pringsheim T, Davenport WJ, Becker WJ. Prophylaxis of migraine headache. CMAJ 2010;182:E269-76
   PubMed Web of Science ®Google Scholar
• Shamliyan TA, Choi JY, Ramakrishnan R, et al. Preventive pharmacologic treatments for episodic migraine in adults. J Gen Intern Med 2013;28:1225-37
   PubMed Web of Science ®Google Scholar
• Jackson JL, Shimeall W, Sessums L, et al. Tricyclic antidepressants and headaches: systematic review and meta-analysis. BMJ 2010;341:c5222
   PubMed Web of Science ®Google Scholar
• Krymchantowski AV, Jevoux C, Bigal ME. Topiramate plus nortriptyline in the preventive treatment of migraine: a controlled study for non responders. J Headache Pain 2012;13:53-9
   PubMed Web of Science ®Google Scholar
• Ioannides-Demos LL, Piccenna L, McNeil JJ. Pharmacotherapies for obesity: past, current, and future therapies. J Obes 2011;2011:179674
   PubMedGoogle Scholar
• Bordeleau L, Pritchard KI, Loprinzi CL, et al. Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors. J Clin Oncol 2010;28:5147-52
   PubMed Web of Science ®Google Scholar
• Bruno A, Micò U, Pandolfo G, et al. Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. J Psychopharmacol 2012;26:1456-62
   PubMed Web of Science ®Google Scholar
• Vieta E, Günther O, Locklear J, et al. Effectiveness of psychotropic medications in the maintenance phase of bipolar disorder: a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol 2011;14:1029-49
   PubMed Web of Science ®Google Scholar
• Pacchiarotti I, Bond DJ, Baldessarini RJ, et al. The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry 2013;170:1249-62
   PubMed Web of Science ®Google Scholar
• Tondo L, Vázquez G, Baldessarini RJ. Mania associated with antidepressant treatment: comprehensive meta-analytic review. Acta Psychiatr Scand 2010;121:404-14
   PubMed Web of Science ®Google Scholar
• Köhler S, Gaus S, Bschor T. The challenge of treatment in bipolar depression: evidence from clinical guidelines, treatment recommendations and complex treatment situations. Pharmacopsychiatry 2014;47:53-9
   PubMed Web of Science ®Google Scholar
• Köster M, Grohmann R, Engel RR, et al. Seizures during antidepressant treatment in psychiatric inpatients – results from the transnational pharmacovigilance project "Arzneimittelsicherheit in der Psychiatrie" (AMSP) 1993-2008. Psychopharmacology (Berl) 2013;230:191-201
   PubMed Web of Science ®Google Scholar
• Alper K, Schwartz KA, Kolts RL, Khan A. Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports. Biol Psychiatry 2007;62:345-54
   PubMed Web of Science ®Google Scholar
• Borowicz KK, Piskorska B, Stępniak B, Czuczwar SJ. Effects of fluoxetine on the anticonvulsant action of valproate and ethosuximide in mouse model of myoclonic convulsions. Ann Agric Environ Med 2012;19:487-90
   PubMed Web of Science ®Google Scholar
• Foianini A, Joseph Wiegand T, Benowitz N. What is the role of lidocaine or phenytoin in tricyclic antidepressant-induced cardiotoxicity? Clin Toxicol (Phila) 2010;48:325-30
   PubMed Web of Science ®Google Scholar
• Schimpf R, Veltmann C, Papavassiliu T, et al. Drug-induced QT-interval shortening following antiepileptic treatment with oral rufinamide. Heart Rhythm 2012;9:776-81
   PubMed Web of Science ®Google Scholar
• Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry 2010;71:1259-72
   PubMed Web of Science ®Google Scholar
• Nicholas LM, Ford AL, Esposito SM, et al. The effects of mirtazapine on plasma lipid profiles in healthy subjects. J Clin Psychiatry 2003;64:883-9
   PubMed Web of Science ®Google Scholar
• Cramer JA. Tolerability of antiepileptic drugs: can we determine differences? Epilepsy Behav 2012;23:187-92
   PubMed Web of Science ®Google Scholar
• Zaccara G, Giovannelli F, Maratea D, et al. Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine. Seizure 2013;22:528-36
   PubMed Web of Science ®Google Scholar
• Gartlehner G, Hansen RA, Thieda P, et al. Comparative Effectiveness of Second-generation Antidepressants in the Pharmacologic Treatment of Adult Depression. Comparative Effectiveness. Review No. 7-EHC007-EF Agency for Healthcare Research and Quality, Rockville, MD; 2007. Available from: http://www.effectivehealthcare.ahrq.gov/repFiles/Antidepressants_Final_Report.pdf [Last accessed 25 June 2014]
   Google Scholar
• Talley NJ. Functional nausea and vomiting. Aust Fam Physician 2007;36:694-7
   PubMed Web of Science ®Google Scholar
• Alam A, Voronovich Z, Carley JA. A review of therapeutic uses of mirtazapine in psychiatric and medical conditions. Prim Care Companion CNS Disord 2013;15(5
   Google Scholar
• Brickel N, Gandhi P, VanLandingham K, et al. The urinary safety profile and secondary renal effects of retigabine (ezogabine): a first-in-class antiepileptic drug that targets KCNQ (K(v)7) potassium channels. Epilepsia 2012;53:606-12
   PubMed Web of Science ®Google Scholar
• Mago R, Mahajan R, Thase ME. Medically serious adverse effects of newer antidepressants. Curr Psychiatry Rep 2008;10:249-57
   PubMedGoogle Scholar
• Dong X, Leppik IE, White J, Rarick J. Hyponatremia from oxcarbazepine and carbamazepine. Neurology 2005;65:1976-8
   PubMed Web of Science ®Google Scholar
• Lange-Asschenfeldt C, Kojda G, Cordes J, et al. Epidemiology, symptoms, and treatment characteristics of hyponatremic psychiatric inpatients. J Clin Psychopharmacol 2013;33:799-805
   PubMed Web of Science ®Google Scholar
• Postema PG, Wolpert C, Amin AS, et al. Drugs and Brugada syndrome patients: review of the literature, recommendations, and an up-to-date website (www.brugadadrugs.org). Heart Rhythm 2009;6:1335-41
   PubMed Web of Science ®Google Scholar
• Kogut C, Breden Crouse E, Vieweg V, et al. Selective serotonin reuptake inhibitors and torsade de pointes: new concepts and new directions derived from a systematic review of cases reports. Ther Adv Drug Saf 2013;4:189-98
   PubMedGoogle Scholar
• Johannesen L, Vicente J, Gray RA, et al. Improving the assessment of heart toxicity for all new drugs through translational regulatory science. Clin Pharmacol Ther 2014;15:501-8
   Google Scholar
• Gahr M, Freudenmann RW, Connemann BJ, et al. Agomelatine and hepatotoxicity: implications of cumulated data derived from spontaneous reports of adverse drug reactions. Pharmacopsychiatry 2013;46:214-20
   PubMed Web of Science ®Google Scholar
• Voican CS, Corruble E, Naveau S, Perlemuter G. Antidepressant-induced liver injury: a review for clinicians. Am J Psychiatry 2014;171:404-15
   PubMed Web of Science ®Google Scholar
• Andrade C, Sandarsh S, Chethan KB, Nagesh KS. Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. J Clin Psychiatry 2010;71:1565-75
   PubMed Web of Science ®Google Scholar
• Köse G, Arhan E, Unal B, et al. Valproate-associated coagulopathies in children during short-term treatment. J Child Neurol 2009;24:1493-8
   PubMed Web of Science ®Google Scholar
• Cheshire WP, Fealey RD. Drug-induced hyperhidrosis and hypohidrosis: incidence, prevention and management. Drug Saf 2008;31:109-26
   PubMed Web of Science ®Google Scholar
• United States Food and Drug Administration. Antidepressant use in children, adolescents, and young adults. Revisions to product labeling. 2007. Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM173233.pdf [Last accessed 25 June 2014]
   Google Scholar
• US Department of Mental Health and Human Services. Statistical review and evaluation: antiepileptic drugs and suicidality. 2008. Available from: http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4372b1-01-FDA.pdf [Last accessed 25 June 2014]
   Google Scholar
• Leon AC, Demirtas H, Li C, Hedeker D. Two propensity score-based strategies for a three-decade observational study: investigating psychotropic medications and suicide risk. Stat Med 2012;31:3255-60
   PubMed Web of Science ®Google Scholar
• Rizzoli R, Cooper C, Reginster JY, et al. Antidepressant medications and osteoporosis. Bone 2012;51:606-13
   PubMed Web of Science ®Google Scholar
• Arrojo-Romero M, Tajes Alonso M, de Leon J. Lamotrigine augmentation of serotonin reuptake inhibitors in severe and long-term treatment-resistant obsessive-compulsive disorder. Case Rep Psychiatry 2013;2013:612459
   Google Scholar